CRISPR Therapeutics Q4 2020 Earnings Report
Key Takeaways
CRISPR Therapeutics reported a net loss of $107.0 million for the fourth quarter of 2020, compared to a net income of $30.5 million for the fourth quarter of 2019. The company's cash, cash equivalents, and marketable securities totaled $1,690.3 million as of December 31, 2020.
More than 20 patients have been dosed with CTX001â„¢ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected in 2021
Additional data from CTX110â„¢ trial expected to report in 2021, along with top-line data from CTX120â„¢ and CTX130â„¢
Total collaboration revenue was $0.2 million for the fourth quarter of 2020 compared to $77.0 million for fourth quarter of 2019
Net loss was $107.0 million for the fourth quarter of 2020 compared to income of $30.5 million for the fourth quarter of 2019
CRISPR Therapeutics
CRISPR Therapeutics
CRISPR Therapeutics Revenue by Segment
Forward Guidance
CRISPR Therapeutics anticipates completing enrollment in CTX001 clinical trials, providing data updates on allogeneic CAR-T programs, bringing the large-scale manufacturing facility online, and building commercial infrastructure in 2021.
Positive Outlook
- Complete enrollment in the CTX001 clinical trials
- Provide data updates on our three clinical allogeneic CAR-T programs
- Make meaningful progress in bringing our large-scale manufacturing facility online
- Building our commercial infrastructure
- Advance programs as we enter a new phase of growth for the company